investorscraft@gmail.com

Stock Analysis & ValuationIterum Therapeutics plc (ITRM)

Previous Close
$0.00
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

Fitzwilliam Court
Dublin 2
IE
Phone: 353 1 669 4820
Industry: Biotechnology
Sector: Healthcare
CEO: Corey N. Fishman
Full Time Employees: 9

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

HomeMenuAccount